Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Inclusion Criteria:

Histologically proven adenocarcinoma of the prostate and: Gleason > 8 OR prostatic specific antigen (PSA) > 20 and more than 1 positive core
Patients with Eastern Cooperative Oncology Group performance scale (ECOG PS) 0 or 1
Clinical stage T3 or less as demonstrated by abdominal/pelvic computed tomography (CT) or magnetic resonance imaging (MRI) will be selected as the prostate is resectable
Hemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization
Platelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 3 months prior to randomization
Serum albumin >= 3.0 g/dL
Glomerular filtration rate (GFR) >= 45 mL/min
Serum potassium >= 3.5 mmol/L
Serum total bilirubin =< 1.5 × upper limit of normal (ULN) (Note: In subjects with Gilbert's syndrome, if total bilirubin is > 1.5 × ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 × ULN, subject may be eligible)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 × ULN
Medications known to lower the seizure threshold must be discontinued or substituted at least 4 weeks prior to study entry
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug

Exclusion Criteria:

Clinical stage T4 (invasion into rectum or ureters) significantly increases the morbidity of the surgery

Patients with rectal or ureteral invasion will be considered to have unresectable disease

History of any of the following:

Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1year to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy)
Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial within 6 months prior to randomization
Venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks) within 6 months prior to randomization
Clinically significant ventricular arrhythmias within 6 months prior to randomization
Metastatic prostate cancer
Baseline moderate or severe hepatic impairment (Child-Pugh class B or C)